dmitrii-guzhanin-istockphoto-com-scales--1
Dmitrii_Guzhanin / iStockphoto.com
18 January 2018Europe

Mixed views on Broad’s fate after EPO revokes CRISPR patent

Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office (EPO) to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
5 February 2026   Excitement is mounting for the world’s largest IP gathering, which will see the industry’s elites travelling to the UK in the spring, reveals the association’s CEO.
Europe
3 February 2026   As legislative activity in life sciences increases, in-house teams are struggling to keep up. Experts share their sources and strategies for monitoring developments, coordinating internally, and knowing when to engage.
Europe
16 January 2026   A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.